Autoimmune and inflammatory diseases associated with primary immunodeficiency: 11 major health stakeholders in France pledge to speed up the development of precision medicine

The Imagine Institute, Sanofi, Ariana Pharmaceuticals, the Paris Public Hospital Network (AP-HP), INRAE (MetaGenoPolis unit), the CEA, the Institut Pasteur, the Institut Curie, Université de Paris, Sorbonne Université and Inserm have announced the signing of a consortium agreement under the French government's Investing in the Future program. The aim of the project is to develop precision medicine for patients with autoimmune and inflammatory diseases associated with primary immunodeficiency.

Find out more (in French)